Emergency Use Authorization
On this page:
- About Emergency Use Authorizations (EUAs)
- PREP Act
- EUA Guidance
- COVID-19 EUAs
- Vaccines
- Convalescent Plasma
- Drugs and Non-Vaccine Biological Products
- Information About COVID-19 EUAs for Medical Devices (including diagnostic tests)
- mpox EUAs
- Vaccines
- Diagnostic tests (monkeypox virus)
- Other Current EUAs
- Related Links
About Emergency Use Authorizations (EUAs)
The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against chemical, biological, radiological, and nuclear (CBRN) threats including infectious diseases, by facilitating the availability and use of medical countermeasures (MCMs) needed during public health emergencies.
Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), when the Secretary of HHS declares that an emergency use authorization is appropriate, FDA may authorize unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when certain criteria are met, including there are no adequate, approved, and available alternatives. The HHS declaration to support such use must be based on one of four types of determinations of threats or potential threats by the Secretary of HHS, Homeland Security, or Defense.
Please note: a determination under section 319 of the Public Health Service Act that a public health emergency exists, such as the one issued on January 31, 2020, does not enable FDA to issue EUAs. On February 4, 2020, the HHS Secretary determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Subsequent HHS declarations supporting use of EUAs and based on this determination are described in the blue boxes below.
Information on terminated and revoked EUAs can be found in archived information.
Public Readiness and Emergency Preparedness Act (PREP Act)
Information on the PREP Act can be found here.
The PREP Act amended the Public Health Service Act (PHS Act) to add section 319F-3 (42 U.S.C. 247d-6d). The HHS Secretary has issued several Declarations pursuant to section 319F-3 of the PHS Act to provide liability immunity for activities related to medical countermeasures against COVID-19.
PREP Act - COVID-19 Related Information
- Notice of Declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID-19 (February 4, 2020)
- COVID-19 PREP Act Declarations and Amendments (HHS)
- Advisory Opinion 02-02 on the PREP Act and the Secretary's Declaration under the Act (PDF, 278 KB, May 19, 2020)
- Fact Sheet: HHS Announces Intent to Amend the Declaration Under the PREP Act for Medical Countermeasures Against COVID-19 (April 14, 2023)
Guidance
In January 2017, FDA finalized the guidance: Emergency Use Authorization of Medical Products and Related Authorities. For more information, please see the January 13, 2017 Federal Register notice.
In addition, in January 2014, FDA issued a question and answer document (PDF, 762K) to respond to questions raised by public health stakeholders about PAHPRA’s amendments to the EUA authority and establishment of new authorities related to the emergency use of MCMs during CBRN emergencies.
Coronavirus Disease 2019 (COVID-19) EUA Information
FDA expects the COVID-19 public health emergency (PHE) declared by the Department of Health and Human Services under the Public Health Service Act to expire on May 11, 2023. The ending of the COVID-19 PHE will not impact FDA's ability to authorize medical countermeasures for emergency use. Existing COVID-19 EUAs will remain in effect, and the agency may continue to issue new EUAs if the situation meets the criteria to do so. Read more about what happens to EUAs when a public health emergency ends.
- Coronavirus Disease (COVID-19) updates from FDA
- Detailed Information for all COVID-19 EUAs, including authorizations and fact sheets
- COVID-19 EUAs for Vaccines
- COVID-19 EUA for Convalescent Plasma
- COVID-19 EUAs for Drugs and Non-Vaccine Biological Products
- COVID-19 EUAs for Medical Devices, including:
- Blood Purification Devices EUAs
- Continuous Renal Replacement Therapy and Hemodialysis Devices EUAs
- In Vitro Diagnostics EUAs
- Decontamination Systems for Personal Protective Equipment EUAs
- Infusion Pump EUAs
- Personal Protective Equipment EUAs
- Remote or Wearable Patient Monitoring Devices EUAs
- Respiratory Assist Devices EUAs
- Ventilators and Ventilator Accessories EUAs
- Other Medical Device EUAs
- Information About COVID-19 EUAs for Medical Devices
Vaccines
The HHS Secretary declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to section 564 of the FD&C Act, effective March 27, 2020. The EUAs subsequently issued by FDA are listed in the table below this blue box.
- Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the FD&C Act (February 4, 2020)
- Amended Determination of a Public Health Emergency or Significant Potential for a Public Health Emergency Pursuant to Section 564(b) of the FD&C Act (effective March 15, 2023; Federal Register notice March 20, 2023)
- Emergency Use Authorization Declaration (March 27, 2020)
For additional information about COVID-19 vaccines, see:
- COVID-19 Vaccines
- Emergency Use Authorization for Vaccines Explained
- Infographic: The Path for a COVID-19 Vaccine From Research to Emergency Use Authorization (PDF, 723 KB)
- Vaccine EUA Questions and Answers for Stakeholders
- Coronavirus (COVID-19) | CBER-Regulated Biologics (including archived fact sheets for monovalent mRNA COVID-19 vaccines, located in a drop-down section at the bottom of the page)
| Date of First EUA Issuance | Most Recent Letter of Authorization (PDF) | Authorized Use | Fact Sheets and Manufacturer Instructions/Package Insert (PDF) | Additional Information and Decision Memoranda (PDF) | Federal Register Notice for EUA |
|---|---|---|---|---|---|
| 07/13/2022 |
Novavax COVID-19 Vaccine, Adjuvanted (892KB) (Reissued August 19, September 12, and October 19, 2022) |
For the prevention of Coronavirus Disease 2019 (COVID-19) for individuals 18 years of age and older |
Healthcare Providers (600KB, updated March 28, 2023) Recipients and Caregivers (708KB, updated October 19, 2022) |
More information about the Novavax COVID-19 Vaccine Decision Memorandum (2.16MB, July 13, 2022) Decision Memorandum (1.81MB, August 19, 2022) Decision Memorandum (812KB, October 19, 2022) |
|
| 02/27/2021 |
Janssen COVID-19 Vaccine (413KB) (Reissued June 10, October 20 and November 19, 2021, May 5, 2022, and March 13, 2023) Letter Granting EUA Amendment (March 29, 2021) (152KB) Letter Granting EUA Amendment (April 23, 2021) (229KB) Concurrence Letter (June 10, 2021) (26KB) Concurrence Letter (June 15, 2021) (57KB) Concurrence Letter (June 16, 2021) (70KB) Concurrence Letter (July 2, 2021) (317.7KB) Letter Granting EUA Amendment (July 12, 2021) (210KB) Concurrence Letter (July 13, 2021) (213KB) Concurrence Letter (July 28, 2021) (63KB) Letter Granting EUA Amendment (August 30, 2021) (80KB) Concurrence Letter (September 8, 2021) (353KB) Concurrence Letter (September 14, 2021) (253KB) Concurrence Letter (September 29, 2021) (28KB) Concurrence Letter (November 5, 2021) (212KB) Letter Granting EUA Amendment (December 14, 2021) (253KB) Letter Granting EUA Amendment (January 11, 2022) (439KB) Letter Granting EUA Amendment (January 31, 2022) (393KB) Concurrence Letter (March 4, 2022) (33KB) Concurrence Letter (April 7, 2022) (136KB) |
For the prevention of Coronavirus Disease 2019 (COVID-19) for individuals 18 years of age and older for whom other FDA-authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and in individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine |
Healthcare Providers (634KB, updated March 13, 2023) Recipients and Caregivers (294KB, updated March 13, 2023) |
More information about the Janssen COVID-19 Vaccine COVID-19 Vaccine Expiration Dating Extensions Decision Memorandum (974KB, February 2021 initial EUA issuance) Decision Memorandum (362KB, June 2021 EUA reissuance) Decision Memorandum Addendum (59KB, June 2021 EUA reissuance) Decision Memorandum Addendum (61KB, July 1, 2021 Assessment of Certain Janssen COVID-19 Vaccine Batches) Decision Memorandum Addendum (58KB, July 13, 2021 Assessment of Certain Janssen COVID-19 Vaccine Batches) Decision Memorandum Addendum (60KB, September 8, 2021 Assessment of Certain Janssen COVID-19 Vaccine Batches) Decision Memorandum Addendum (55KB, September 14, 2021 Assessment of Certain Janssen COVID-19 Vaccine Batches) Decision Memorandum Addendum (57KB, September 29, 2021 Assessment of Certain Janssen COVID-19 Vaccine Batches) Decision Memorandum (605KB, October 20, 2021 EUA reissuance) Memorandum to the File (940KB, October 20, 2021 EUA amendment to support use of a Janssen COVID-19 Vaccine heterologous booster dose following primary vaccination with other authorized COVID-19 vaccines) Decision Memorandum Addendum (59KB, November 5, 2021 Assessment of Certain Janssen COVID-19 Vaccine Batches) Decision Memorandum Addendum (64KB, November 18, 2021) Review Memorandum (86KB, December 22, 2021) Addendum to Dec. 22, 2021 Review Memorandum (398KB, December 22, 2021) Decision Memorandum Addendum (87KB, December 30, 2021) Decision Memorandum Addendum (87KB, January 6, 2022) Review Memorandum (84KB, January 7, 2022) Addendum to Jan 7, 2022 Review Memorandum (81KB, January 7, 2022) Decision Memorandum (257KB, May 5, 2022) Decision Memorandum (542KB, March 13, 2023) |
|
| 12/18/2020 |
Moderna COVID-19 Vaccine (1.43MB) (Reissued February 25, July 7, August 12, October 20, and November 19, 2021, January 7, January 31, March 15, March 29, June 17, August 31, October 12, December 8, 2022, and April 18, 2023) Letter Granting EUA Amendment (April 1, 2021) (193KB) Letter Granting EUA Amendment (June 25, 2021) (90KB) Letter Granting EUA Amendment (August 30, 2021) (58KB) Letter Granting EUA Amendment (December 9, 2021) (192KB) Concurrence Letter (September 20, 2022) (886KB) Concurrence Letter (September 26, 2022) (137KB) Concurrence Letter (September 28, 2022) (139KB) Concurrence Letter (October 6, 2022) (174KB) Concurrence Letter (October 14, 2022) (177KB) Concurrence Letter (October 20, 2022) (172KB) Concurrence Letter (October 28, 2022) (190KB) Concurrence Letter (November 4, 2022) (138KB) Concurrence Letter (November 4, 2022) (177KB) Concurrence Letter (November 19, 2022) (171KB) Concurrence Letter (November 28, 2022) (176KB) |
For the prevention of 2019 coronavirus disease (COVID-19) in individuals 6 months and older On January 31, 2022, FDA approved the Moderna COVID-19 Vaccine, now known as Spikevax, for the prevention of COVID-19. |
Healthcare Providers (968KB, April 18, 2023) Recipients and Caregivers (189KB, April 18, 2023) Moderna Dear Healthcare Provider Letter (304KB, April 18, 2023) |
More information about the Moderna COVID-19 Vaccine Decision Memorandum (769KB) Decision Memorandum (65KB, August 12, 2021 EUA reissuance) Decision Memorandum (606KB, October 20, 2021 EUA reissuance) Memorandum to the File (605KB, October 20, 2021 EUA amendment to support use of a Moderna COVID-19 Vaccine heterologous booster dose following primary vaccination with other authorized COVID-19 vaccines) Decision Memorandum Addendum (89KB, November 18, 2021) Decision Memorandum (85KB, November 19, 2021) Decision Memorandum Addendum (101KB, November 19, 2021) Decision Memorandum Addendum (92KB, December 30, 2021) Decision Memorandum (112KB, January 6, 2022) Decision Memorandum (278KB, March 28, 2022) Decision Memorandum (2.48MB, June 17, 2022) Decision Memorandum (703KB, August 31, 2022) Decision Memorandum (193KB, September 20, 2022) Decision Memorandum Addendum (183KB, September 26, 2021) Decision Memorandum Addendum #2 (188KB, September 28, 2021) Decision Memorandum Addendum #3 (183KB, October 6, 2022) Decision Memorandum Addendum #4 (184KB, October 14, 2022) Decision Memorandum Addendum #5 (183KB, October 20, 2022) Decision Memorandum (2.63MB, October 12, 2022) Decision Memorandum Addendum #6 (184KB, October 28, 2022) Decision Memorandum Addendum #7 (183KB, November 4, 2022) Decision Memorandum Addendum #8 (183KB, November 19, 2022) Decision Memorandum Addendum #9 (182KB, November 28, 2022) Decision Memorandum (865KB, December 8, 2022) Decision Memorandum (482KB, April 18, 2023) |
|
| 12/11/2020 |
Pfizer-BioNTech COVID-19 Vaccine (581KB) (Reissued February 25, May 10, June 25, August 12, August 23, September 22, October 20, October 29, November 19, December 9, December 16, 2021, January 3, March 29, May 17, June 17, July 8, August 31, October 12, December 8, 2022, March 14, 2023, April 18, 2023, and April 28, 2023) Letter Granting EUA Amendment (January 6, 2021) (164KB) Letter Granting EUA Amendment (January 22, 2021) (190KB) Letter Granting EUA Amendment (April 6, 2021) (166KB) Letter Granting EUA Amendment (May 19, 2021) (184KB) Concurrence Letter (August 22, 2021) (68KB) Letter Granting EUA Amendment (September 1, 2021) (98KB) Letter Granting EUA Amendment (January 31, 2022) (170KB) Letter Granting EUA Amendment (April 13, 2022) (375KB) Letter Granting EUA Amendment (April 26, 2022) (179KB) Letter Granting EUA Amendment (June 1, 2022) (164KB) Letter Granting EUA Amendment (June 28, 2022) (128KB) Letter Granting EUA Amendment (October 18, 2022) (203KB) Letter Granting EUA Amendment (November 22, 2022) (347KB) Letter Granting EUA Amendment (December 22, 2022) (204KB) |
For the prevention of 2019 coronavirus disease (COVID-19) in individuals 6 months and older On August 23, 2021, FDA approved the Pfizer-BioNTech COVID-19 Vaccine, now known as Comirnaty, for the prevention of COVID-19. |
Healthcare Providers (1.04MB, April 28, 2023) Recipients and Caregivers (212KB, April 28, 2023) |
More information about the Pfizer-BioNTech COVID-19 Vaccine COVID-19 Vaccine Expiration Dating Extensions Decision Memorandum (709KB, December 2020 initial EUA issuance) Decision Memorandum (868KB, May 2021 EUA reissuance) Decision Memorandum (93KB, August 12, 2021 EUA reissuance) Decision Memorandum (362KB, September 24, 2021) Decision Memorandum (630KB, October 20, 2021 EUA reissuance) Decision Memorandum (508KB, October 29, 2021) Decision Memorandum (135KB, November 19, 2021) Decision Memorandum Addendum (96KB, November 19, 2021) Decision Memorandum (135KB, December 8, 2021) Decision Memorandum (140KB, December 30, 2021) Decision Memorandum Addendum (87KB, January 6, 2022) Decision Memorandum (279KB, March 28, 2022) Decision Memorandum (481KB, May 17, 2022 Decision Memorandum (973KB, June 17, 2022) Decision Memorandum (962KB, August 31, 2022) Decision Memorandum (382KB, October 12, 2022) Decision Memorandum (230KB, November 18, 2022) Decision Memorandum (394KB, December 8, 2022) Decision Memorandum (602KB, March 14, 2023) Decision Memorandum (571KB, April 18, 2023) Decision Memorandum (KB, April 28, 2023) |
Convalescent Plasma
The HHS Secretary declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to section 564 of the FD&C Act, effective March 27, 2020. The EUA subsequently issued by FDA is listed in the table below this blue box.
- Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the FD&C Act (February 4, 2020)
- Amended Determination of a Public Health Emergency or Significant Potential for a Public Health Emergency Pursuant to Section 564(b) of the FD&C Act (effective March 15, 2023; Federal Register notice March 20, 2023)
- Emergency Use Authorization Declaration (March 27, 2020)
Also see: Recommendations for Investigational COVID-19 Convalescent Plasma
| Date of First EUA Issuance | Most Recent Letter of Authorization (PDF) | Authorized Use | Fact Sheets and Manufacturer Instructions/Package Insert (PDF) | Federal Register Notice for EUA |
|---|---|---|---|---|
| 08/23/2020 |
COVID-19 convalescent plasma (365KB) (Reissued February 23, 2021, March 9, 2021 and December 28, 2021) Letter Granting EUA Amendment (June 2, 2021) (107KB) Letter Granting EUA Amendment (February 9, 2022) (26KB)
|
COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies is authorized for the treatment of COVID-19 in patients with immunosuppressive disease or receiving immunosuppressive treatment, in inpatient or outpatient settings. |
Healthcare Providers (Updated December 28, 2021) (192KB) Patients and Parents/ Caregivers (Updated December 28, 2021) (151KB) Decision Memorandum (166KB) Decision Memorandum (December 27, 2021) (242KB) |
Drugs and Non-Vaccine Biological Products
View the list Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products, for additional information including letters of authorization, fact sheets, Dear Health Care Provider letters, and additional information about COVID-19 therapeutics.
The HHS Secretary declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to section 564 of the FD&C Act, effective March 27, 2020. The EUAs subsequently issued by FDA are listed in the table on the page: Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products.
- Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the FD&C Act (February 4, 2020)
- Amended Determination of a Public Health Emergency or Significant Potential for a Public Health Emergency Pursuant to Section 564(b) of the FD&C Act (effective March 15, 2023; Federal Register notice March 20, 2023)
- Emergency Use Authorization Declaration (March 27, 2020)
The dashboard provides weekly updates of adverse event reports submitted to FAERS for drugs and therapeutic biological products used under EUA during the COVID-19 public health emergency. After launching the FAERS Public Dashboard, click on the COVID-19 EUA link at the top of the home page to open the COVID-19 EUA FAERS Public Dashboard.
View the FDA’s COVID-19 Drugs page to see all products approved to treat COVID-19 without any remaining EUA authorized uses.
Revocation notices for COVID-19 drug and biological product EUAs are available at: Emergency Use Authorization--Archived Information.
Related links:
Information About COVID-19 EUAs for Medical Devices
Information about COVID-19 EUAs for medical devices can be found below and at: Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices.
Transition guidances update
March 24, 2023 - The FDA finalized two guidances: Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency and Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19). The guidances outline the FDA’s general recommendations to transition from certain policies adopted and operations implemented during the COVID-19 pandemic to normal operations, including the FDA’s recommendations for:
- Developing a transition implementation plan,
- Submitting a marketing submission, and
- Taking other actions with respect to these devices.
The FDA encourages stakeholders to review the two final guidances, attend the webinar noted below, and reach out to the FDA if they have questions. In particular, for manufacturers that are planning to seek marketing authorization for their devices, the FDA recommends beginning work on a marketing submission, including a transition implementation plan, as described in the guidances.
Additional resources:
- Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency
- Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19)
- Webinar on Guidances on COVID-19 Transition Plans for Medical Devices (April 18, 2023)
Declaration and determination
On February 4, 2020, the Secretary determined pursuant to section 564 of the FD&C Act that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad and that involves a novel (new) coronavirus (nCoV) first detected in Wuhan City, Hubei Province, China in 2019 (2019-nCoV).
On the basis of this determination, the HHS Secretary issued three declarations related to medical devices:
- Determination of Public Health Emergency (effective February 4, 2020), and declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19
- Amended Determination of a Public Health Emergency or Significant Potential for a Public Health Emergency Pursuant to Section 564(b) of the FD&C Act (effective March 15, 2023; Federal Register notice March 20, 2023)
- Emergency Use Declaration (effective March 2, 2020), that circumstances exist justifying the authorization of emergency use of personal respiratory protective devices during the COVID-19 outbreak
- Emergency Use Authorization Declaration (effective March 24, 2020), that circumstances exist justifying the authorization of emergency use of medical devices, including alternative products used as medical devices, due to shortages during the COVID-19 outbreak
For identification of the applicable declaration for each EUA, please see each EUA letter of authorization and/or the corresponding Federal Register notice.
Please see the page In Vitro Diagnostics EUAs for information about in vitro diagnostics EUAs, including templates.
For current SARS-CoV-2 in vitro diagnostic EUAs, see:
- Molecular Diagnostic Tests for SARS-CoV-2
- Antigen Diagnostic Tests for SARS-CoV-2
- Serology and Other Adaptive Immune Response Tests for SARS-CoV-2
- IVDs for Management of COVID-19 Patients
On February 29, 2020, the FDA issued an immediately in effect guidance with policy specific to development of in vitro diagnostic tests during this public health emergency. This guidance was updated on March 16, 2020, May 4, 2020, and May 11, 2020. On September 27, 2022, FDA updated this policy to ensure continued access to tests while encouraging the transition of these important public health tools to traditional premarket review pathways. The updated policy describes the FDA’s intent to review only a small subset of new EUA requests for diagnostic tests and encourages developers of all test types interested in marketing authorization to pursue authorization through the de novo classification or 510(k) clearance pre-market review pathways.
CDC has granted a right of reference to the performance data contained in CDC's EUA (FDA submission number EUA200001) to any entity seeking an FDA EUA for a COVID-19 diagnostic device.
Templates for these EUA submissions are available to help facilitate the preparation, submission, and authorization of an EUA.
For additional information, see Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised), FAQs on Diagnostic Testing for SARS-CoV-2, EUA Authorized Serology Test Performance, and CLIA and University Laboratory Testing FAQ (CMS).
For a list of all molecular SARS-CoV-2 diagnostic tests that have been cleared or granted De Novo classification, see devices with product codes QOF and QQX in FDA’s medical devices databases for 510(k) and De Novo. For a list of all antigen SARS-CoV-2 diagnostic tests that have been cleared or granted De Novo classification, see devices with product code QVF in FDA’s medical devices databases for 510(k) and De Novo.
Please see the page Personal Protective Equipment EUAs for current EUAs.
For additional information, see Recent Final Medical Device Guidance Documents, and Non-NIOSH Approved Respirator FAQ.
See Revoked EUAs for Non-NIOSH-Approved Disposable Filtering Facepiece Respirators and Decontamination and Bioburden Reduction Systems below for information about June 30, 2021 EUA revocations.
Please see the following pages for EUA templates and additional information about other types of medical device EUAs for COVID-19:
On June 30, 2021, the FDA announced the revocation of the following EUAs:
- Imported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators (effective July 6, 2021)
- Non-NIOSH-Approved Disposable Filtering Facepiece Respirators Manufactured in China (effective July 6, 2021)
- Decontamination and Bioburden Reduction System EUAs for Personal Protective Equipment (effective June 30, 2021)
As of the effective date of the revocations, these devices will no longer be authorized for use by health care personnel in health care settings.
For additional information, please see Update: FDA No Longer Authorizes Use of Non-NIOSH-Approved or Decontaminated Disposable Respirators - Letter to Health Care Personnel and Facilities.
Historical information regarding these EUAs can be found on Historical Information about Device Emergency Use Authorizations and Emergency Use Authorization--Archived Information.
- Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability (through April 10, 2020)
- Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability (April 11, 2020- May 15, 2020)
- Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability (May 15, 2020- September 14, 2020)
- Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability (September 15, 2020 - February 15, 2021)
- Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability (February 16, 2021- May 31, 2021)
- Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability (June 1, 2021 - September 10, 2021)
- Emergency Use Authorization: Certain Medical Devices during COVID-19 (September 11, 2021 - January 24, 2022)
- Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability (January 25, 2022 - June 15, 2022)
- Emergency Use Authorization: Certain Medical Devices during COVID-19 (June 16, 2022 - December 6, 2022)
- Emergency Use Authorization: Certain Medical Devices during COVID-19 (December 7, 2022 - February 24, 2023)
- Authorization of Emergency Use of a Medical Device During COVID-19; Availability (March 24, 2023)
- Authorization and Revocations of Emergency Use of Certain In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability (for one authorization effective May 28, 2021, and three revocations effective July 19, 2022)
- Revocation notices for device EUAs are available at: Historical Information about Device Emergency Use Authorizations
mpox EUA Information
mpox Vaccine EUAs
On November 28, 2022, the World Health Organization announced, and the U.S. government supported, renaming monkeypox disease to mpox. In response to this action by the WHO, federal public health agencies will adopt the mpox name in correspondence with the medical community and American public from this point forward.
Effective August 9, 2022, pursuant to section 564 of the FD&C Act, the HHS Secretary declared:
- There is a public health emergency related to monkeypox, or significant potential for a public health emergency, that affects, or has the significant potential to affect, national security or the health and security of United States citizens living abroad that involves monkeypox virus; and
- On the basis of this determination, circumstances exist justifying the authorization of emergency use of vaccines.
Vaccine EUAs subsequently issued by FDA are listed in the table below.
PREP Act declaration: Effective September 28, 2022, the HHS Secretary amended the declaration first issued on October 10, 2008, and amended and republished effective January 1, 2016 for smallpox countermeasures and countermeasures against other orthopoxviruses pursuant to section 319F-3 of the Public Health Service Act to emphasize that the declaration applies to monkeypox virus, to expand the categories of providers authorized to administer vaccines and therapeutics against smallpox (variola virus), monkeypox virus, and other orthopoxviruses in a declared emergency, and to extend the duration of the declaration. About PREP Act declarations
| Date of First EUA Issuance | Letter of Authorization (PDF) | Authorized Use | Fact Sheets and Manufacturer Instructions/Package Insert (PDF) | Additional Information and Decision Memoranda (PDF) | Federal Register Notice for EUA |
|---|---|---|---|---|---|
| August 9, 2022 |
Jynneos (602KB) Letter granting EUA amendment (August 16, 2022) (133KB) |
|
Healthcare Providers (343KB) (updated August 16, 2022) Recipients and Caregivers (465KB)
Dear Healthcare Provider Letter (290KB) |
Decision Memorandum (295KB) |
Authorization of Emergency Use of a Biological Product in Response to an Outbreak of Monkeypox; Availability (October 7, 2022) |
mpox In Vitro Diagnostics EUAs
Effective September 7, 2022, pursuant to section 564 of the FD&C Act, the HHS Secretary declared:
- On the basis of the August 9th determination, the Secretary of HHS has subsequently declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of infection with the monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola Orthopoxvirus, pursuant to section 564 of the FD&C Act, subject to the terms of any authorization issued under that section. See from HHS: HHS Secretary Becerra Issues 564 Declaration to Expand the Availability of Testing for Monkeypox
Diagnostic EUAs subsequently issued by FDA are listed in the table on this page: Monkeypox Emergency Use Authorizations for Medical Devices.
Additional information for product developers is available at:
- Policy for Monkeypox Tests to Address the Public Health Emergency
- Monkeypox Emergency Use Authorizations for Medical Devices (including EUA templates)
Note that FDA previously cleared real-time polymerase chain reaction (PCR) tests that detect non-variola orthopoxvirus DNA, including the virus that causes mpox. Learn more about these tests: Monkeypox Tests (In Vitro Diagnostic (IVD) Devices).
On October 20, 2022, FDA also published lists of certain laboratories that have notified FDA of their laboratory developed monkeypox diagnostic test (LDT), modification to an FDA-cleared or EUA-authorized monkeypox diagnostic test, or laboratory developed monkeypox serology test, as described in Sections IV.A.2, IV.A.3, and IV.C, respectively, of the Policy for Monkeypox Tests to Address the Public Health Emergency. While FDA has not reviewed the laboratory’s validation of the listed tests and has not issued EUAs for these tests, we are providing this information to promote transparency.
For additional information about monkeypox (mpox), see: FDA mpox Response and Monkeypox and Medical Devices.
Other Current EUAs
The tables below provide information on current EUAs:
- Anthrax EUAs
- Ebola Virus EUA Information
- Freeze Dried Plasma Information
- H7N9 Influenza EUA Information
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV) EUA Information
- Nerve Agent EUA Information
- Zika Virus EUA Information
Information about EUAs that are no longer in effect is available on our EUA archive page.
The 2016 FDA Doxycycline Emergency Dispensing Order and CDC Doxycycline Emergency Use Instructions (EUI) together replace the need for the doxycycline mass dispensing EUA (issued on July 21, 2011). Therefore, the doxycycline emergency dispensing order and EUI should be used by stakeholders for anthrax preparedness and response instead of the mass dispensing EUA.
The July 21, 2011, doxycycline mass dispensing EUA, and the October 14, 2011, National Postal Model anthrax EUA will be terminated by FDA, and notice of such termination will be published in the Federal Register. For additional information, see Emergency Use Authorization--Archived Information.
Ebola preparedness and response updates from FDA (all agency activities)
For more information about the diagnostics below, also see Emergency Use Authorizations for Medical Devices: 2014 Ebola Virus Emergency Use Authorizations.
Ebola Diagnostic Tests with De Novo, 510(k) or PMA
- OraQuickEbola Rapid Antigen Test - On October 10, 2019, FDA allowed marketing (PDF, 255 KB) of a rapid diagnostic test (RDT) to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola (cadaveric oral fluid). The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the U.S. for Ebola virus disease (EVD). The test provides a rapid, presumptive diagnosis that must be confirmed. Also see the FDA news release: FDA allows marketing of first rapid diagnostic test for detecting Ebola virus antigens
The OraQuick Ebola Test was reviewed under the De Novo premarket review pathway, a regulatory pathway for low-to-moderate-risk devices of a new type. Along with this marketing authorization, the FDA is establishing criteria, called special controls, that determine the requirements for demonstrating accuracy, reliability and effectiveness of tests intended to identify Ebola virus antigens. These special controls, when met along with general controls, provide a reasonable assurance of safety and effectiveness for tests of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA’s 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
EZ1 Real-time RT-PCR Assay |
August 5, 2014 (initial issuance) October 10, 2014 (reissuance)
|
Authorization (PDF, 61 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
CDC Ebola Virus NP Real-time RT-PCR Assay |
October 10, 2014 (initial issuance) March 2, 2015 (reissuance) October 8, 2019 (amended)
|
Authorization (PDF, 282 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
CDC Ebola Virus VP40 Real-time RT-PCR Assay |
October 10, 2014 (initial issuance) March 2, 2015 (reissuance) October 8, 2019 (amended)
|
Authorization (PDF, 285 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
FilmArray Biothreat-E test |
October 25, 2014 November 12, 2019 (amended) |
Authorization (PDF, 73 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
RealStar Ebolavirus RT-PCR Kit 1.0 |
November 10, 2014 (initial issuance) November 26, 2014 (reissuance)
|
Authorization (PDF, 263 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
LightMix Ebola Zaire rRT-PCR Test |
December 23, 2014 |
Authorization (PDF, 2.2 MB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
Xpert Ebola Assay |
March 23, 2015 |
Authorization (PDF, 240 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
||
|
DPP Ebola Antigen System (Chembio Diagnostic Systems, Inc.) |
November 9, 2018 April 2, 2019 (amended) |
Authorization (PDF, 103 KB) Letter Granting EUA Amendment(s) (PDF, 87 KB) |
|
Declaration Regarding Emergency Use of In Vitro Diagnostics for Detection of Ebola Virus (August 4, 2014) |
Also see FDA News Release: FDA takes action to support American military personnel by granting an authorization for freeze-dried plasma product to enable broader access while the agency works toward approval of the product (July 10, 2018)
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
Pathogen-Reduced Leukocyte-Depleted Freeze Dried Plasma (Centre de Transfusion Sanguine des Armées)
|
July 9, 2018 (initial issuance) May 8, 2020 (amendment) |
Authorization (PDF, 203 KB) Letter granting EUA amendments (PDF, 60 KB) |
|
Determination by DoD (June 7, 2018) Declaration Regarding Emergency Use of Treatment for Hemorrhage or Coagulopathy During an Emergency Involving Agents of Military Combat (July 9, 2018) |
For more information about the diagnostics below, also see Emergency Use Authorizations for Medical Devices: 2013 H7N9 Influenza Emergency Use Authorization (Potential Emergency).
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheet and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel-Influenza A/H7 (Eurasian Lineage) Assay |
April 22, 2013 (initial issuance)
March 27, 2018 (reissuance) |
Authorization (PDF, 301 KB), re-issued March 27, 2018
|
|
Determination and Declaration Regarding Emergency Use of in Vitro Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013) |
Pandemic Influenza Medical Countermeasures-Amendment (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
|
|
Quidel Lyra Influenza A Subtype H7N9 Assay |
February 14, 2014 |
Authorization (PDF, 57 KB) |
|
Determination and Declaration Regarding Emergency Use of in Vitro Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013) |
Pandemic Influenza Medical Countermeasures-Amendment (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
|
|
A/H7N9 Influenza Rapid Test |
April 25, 2014 |
Determination and Declaration Regarding Emergency Use of in Vitro Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013) |
Pandemic Influenza Medical Countermeasures-Amendment (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
For more information about the diagnostics below, also see Emergency Use Authorizations for Medical Devices: 2013 Coronavirus Emergency Use Authorization (Potential Emergency).
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
CDC Novel Coronavirus 2012 Real-time RT-PCR Assay |
June 5, 2013 (initial issuance) June 10, 2014 (reissuance)
|
Authorization (PDF, 2.2 MB) |
|
|
||
|
RealStar MERS-CoV RT-PCR Kit U.S. |
July 17, 2015 February 12, 2016 (reissuance)
|
Authorization (PDF, 238 KB) |
|
On July 9, 2018, FDA approved (PDF, 49 KB) the 2 mg Atropine Auto-Injector manufactured by Rafa Laboratories, Ltd., for the treatment of poisoning by susceptible organophosphorous nerve agents having cholinesterase activity as well as organophosphorous or carbamate insecticides in adults and pediatric patients weighing over 90 lbs [41 kg] (generally over 10 years of age). For more information about the approved 2 mg Rafa Atropine Auto-Injector, see the product label (PDF, 482 KB). The EUA detailed in the table below is still in effect.
| Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
Atropine Auto-Injector (Rafa Laboratories Ltd.) |
April 11, 2017 (initial issuance) May 23, 2017 (amended) January 24, 2018 (amended) March 6, 2018 (amended) May 15, 2018 (amended) |
Letter of Authorization (PDF, 514 KB) Letter granting EUA amendment(s) (PDF, 28 KB) 2nd letter granting EUA amendment(s) (PDF, 33 KB) 3rd letter granting EUA amendment(s) (PDF, 85 KB) 4th letter granting EUA amendment(s) (PDF, 42 KB) |
|
Determination and Declaration Regarding Nerve Agent or Certain Insecticide (Organophosphorus and/or Carbamate) Poisoning (April 11, 2017) |
Nerve Agents and Certain Insecticides (Organophosphorus and/or Carbamate) Countermeasures (April 11, 2017) |
Zika virus response updates from FDA
For more information about the diagnostics below, also see Emergency Use Authorizations for Medical Devices: Zika Virus Emergency Use Authorization.
Draft EUA review templates for Zika are available by email request to: CDRH-ZIKA-Templates@fda.hhs.gov
Laboratory personnel using Zika diagnostic assays under EUA are encouraged to report performance concerns directly to FDA at CDRH-EUA-Reporting@fda.hhs.gov, in addition to reporting concerns to the manufacturer.
Zika Diagnostic Tests with De Novo, 510(k), or PMA
- ZIKV Detect 2.0 IgM Capture ELISA - On May 23, 2019, FDA authorized marketing (PDF, 175 KB) of the ZIKV Detect 2.0 IgM Capture ELISA to detect Zika virus immunoglobulin (IgM) antibodies in human blood. The ZIKV Detect 2.0 IgM Capture ELISA is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies—including the ZIKV Detect 2.0 IgM Capture ELISA—had been authorized only for emergency use under the FDA’s EUA authority. Also see the FDA news release: FDA authorizes marketing of first diagnostic test for detecting Zika virus antibodies
- ADVIA Centaur Zika test – On July 17, 2019, FDA cleared the ADVIA Centaur Zika test. This is the second Zika diagnostic test FDA has allowed to be marketed in the U.S. for detecting Zika virus IgM antibodies. Previously, the test had been authorized only for emergency use under FDA’s EUA authority.
- LIAISON XL Zika Capture IgM Assay II – On October 28, 2019, FDA cleared the LIAISON XL Zika Capture IgM Assay II for detecting Zika virus IgM antibodies. Previously, the test had been authorized only for emergency use under FDA’s EUA authority.
- DPP Zika IgM Assay System – On June 3, 2020, FDA cleared a similar DPP Zika IgM System for detecting Zika virus IgM antibodies. Previously, the test had been authorized only for emergency use under FDA’s EUA authority.
| Medical Product | Date of EUA Issuance | Letters | Federal Register Notice for EUA |
Fact Sheets and Manufacturer Instructions/Package Insert |
EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
|---|---|---|---|---|---|---|
|
CDC Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay |
February 26, 2016 (initial issuance) June 29, 2016 (amended) November 15, 2016 (amended) December 6, 2016 (amended) May 3, 2017 (amended) July 31, 2017 (amended) April 16, 2018 (amended) September 26, 2018 (amended) |
Letter granting EUA amendment(s) (PDF, 155 KB) Letter granting EUA amendment(s) (PDF, 123 KB) Letter granting EUA amendment(s) (PDF, 110 KB) Letter granting EUA amendment(s) (PDF, 113 KB) Letter granting EUA amendment(s) (PDF, 131 KB) Letter granting EUA amendment(s) (PDF, 131 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
CDC Trioplex Real-time RT-PCR Assay (Trioplex rRT-PCR) |
March 17, 2016 (initial issuance) September 21, 2016 (amended) January 12, 2017 (amended) February 28, 2017 (amended) April 6, 2017 (amended) February 26, 2021 (amended) |
Authorization (PDF, 82 KB) Letter granting EUA amendment(s) (PDF, 223 KB) Letter granting EUA amendment(s) (PDF, 223 KB) Letter granting EUA amendment(s) (PDF, 223 KB) Letter granting EUA amendment(s) (PDF, 126 KB) Letter granting EUA amendment(s) (PDF, 143 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Zika Virus RNA Qualitative Real-Time RT-PCR (Quest Diagnostics Infectious Disease, Inc.) |
April 28, 2016 (initial issuance) October 7, 2016 (reissuance) April 11, 2017 (amended) |
Authorization (PDF, 339 KB) Letter granting EUA amendment(s) (PDF, 126 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
RealStar Zika Virus RT-PCR Kit U.S. (altona Diagnostics GmbH) |
May 13, 2016 (initial issuance) October 31, 2016 (amended) March 6, 2017 (amended) |
Authorization (PDF, 342 KB) Letter Granting EUA Amendment(s) (PDF, 130 KB) Letter Granting EUA Amendment(s) (PDF, 130 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Aptima Zika Virus assay (Hologic, Inc.) |
June 17, 2016 (initial issuance) September 7, 2016 (amended) April 12, 2017 (amended) March 8, 2018 (amended)
|
Authorization (PDF, 305 KB) Letter granting EUA amendment(s) (PDF, 126 KB) Letter granting EUA amendment(s) (PDF, 124 KB) Letter granting EUA amendment(s) (PDF, 130 KB)
|
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Zika Virus Real-time RT-PCR Test (Viracor Eurofins) |
July 19, 2016 (initial issuance) February 28, 2017 (amended) |
Authorization (PDF, 334 KB) Letter granting EUA amendment(s) (PDF, 124 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
VERSANT Zika RNA 1.0 Assay (kPCR) Kit (Siemens Healthcare Diagnostics Inc.) |
July 29, 2016 (initial issuance) December 19, 2016 (amended) |
Authorization (PDF, 78 KB) Letter granting EUA amendment(s) (PDF, 124 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Sentosa SA ZIKV RT-PCR Test (Vela Diagnostics USA, Inc.) |
September 23, 2016 |
Authorization (PDF, 355 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Zika Virus Detection by RT-PCR Test (ARUP Laboratories) |
September 28, 2016 |
Authorization (PDF, 98 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Abbott RealTime ZIKA (Abbott Molecular Inc.) |
November 21, 2016 (initial issuance) January 6, 2017 (amended) |
Authorization (PDF, 84 KB) Letter granting EUA amendment(s) (PDF, 150 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Zika ELITe MGB Kit U.S. (ELITechGroup Inc. Molecular Diagnostics) |
December 9, 2016 |
Authorization (PDF, 312 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
Gene-RADAR Zika Virus Test (Nanobiosym Diagnostics, Inc.) |
March 20, 2017 |
Authorization (PDF, 313 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
|
|
TaqPath Zika Virus Kit (Thermo Fisher Scientific) |
August 2, 2017 |
Authorization (PDF, 292 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016)
|
|
|
|
CII-ArboViroPlex rRT-PCR Assay (Columbia University) |
August 11, 2017 |
Authorization (PDF, 377 KB) |
|
Emergency Use of In Vitro Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Related Links
- Coronavirus Disease 2019 (COVID-19)
- Summary of Process for EUA Issuance
- Current Emergency Use Authorizations for Medical Devices
- FAQs: What happens to EUAs when a public health emergency ends?
- How to Submit a Pre-EUA for In vitro Diagnostics (IVDs) to FDA (for test manufacturers)
- Information for Laboratories Implementing IVD Tests Under EUA
- Process for Publishing Emergency Use Authorizations for Medical Devices During Coronavirus Disease 2019 (June 2, 2020)
- Emergency Use Authorization--Archived Information
- Emergency Dispensing Orders
- 21st Century Cures Act: MCM-Related Cures Provisions
- Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA)
- Public Readiness and Emergency Preparedness (PREP) Act
- HHS Public Health Emergency EUA Authorization Declarations
- Ebola Preparedness and Response Updates from FDA
- Zika Virus Response Updates from FDA
- Historical Information about Device Emergency Use Authorizations